A multi-analyte serum test for the detection of non-small cell lung cancer

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1221-1228

  Farlow, E C ^a,b   Vercillo, M S ^a,b   Coon, J S ^a   Basu, S ^a   Kim, A W ^a   Faber, L P ^a   Warren, W H ^a   Bonomi, P ^a   Liptay, M J ^a   Borgia, J A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diagnosis; Luminex; non small cell lung cancer; serum

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; INTERLEUKIN 1 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SERUM; VALIDATION PROCESS; BLOOD; BLOOD ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; CHEMISTRY; COHORT ANALYSIS; EARLY DIAGNOSIS; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BLOOD CHEMICAL ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SERUM; TUMOR MARKERS, BIOLOGICAL;

EID: 77958018000     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605865     Document Type: Article

References (32)

1. Ashton RW, Jett JR (2005) Screening for non-small cell lung cancer. Semin Oncol 32: 253-258
2. Bates J, Rutherford R, Divilly M, Finn J, Grimes H, O'Muircheartaigh I, Gilmartin JJ (1997) Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J 10: 2535-2538
3. Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93: 453-457 (Pubitemid 43080020)
4. Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH, Bonomi P, Liptay MJ (2009) Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol 4: 338-347
5. Breiman L (2001) Random Forests. Mach Learn 45: 5-32
6. Breiman L, Friedman J, Olshen R, Stone C (1984) Classification and Regression Trees. Chapman & Hall: Monterey, CA
7. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF (2008) Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63: 228-233
8. Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D (2008) Clinical value of combined detection of serum tumor markers in lung cancer diagnosis. Sichuan Da Xue Xue Bao Yi Xue Ban 39: 832-835
9. D'Amico TA, Brooks KR, Joshi MB, Conlon D, Herndon II J, Petersen RP, Harpole Jr DH (2006) Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. Ann Thorac Surg 81: 1982-1987;discussion 1987
10. Gleeson FV (2006) Is screening for lung cancer using low dose spiral CT scanning worthwhile? Thorax 61: 5-7
11. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM (2002) Prognostic value of serum tumor markers in patients with lung cancer. Respiration 69: 25-29
12. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R, Yokomise H (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92: 1231-1239
13. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J (2006) Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 70: 115-125
14. Kaya A, Ciledag A, Gulbay BE, Poyraz BM, Celik G, Sen E, Savas H, Savas I (2004) The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98: 632-636
15. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR (2004) Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22: 4575-4583
16. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, Patz Jr EF, Swensen SJ (2005) Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 237: 395-400
17. McWilliams A, Lam S (2005) Lung cancer screening. Curr Opin Pulm Med 11: 272-277
18. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P (2003) Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218
19. Mulshine JL, Sullivan DC (2005) Clinical practice. Lung cancer screening. N Engl J Med 352: 2714-2720
20. Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H, Fischer JR (2002) Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 101: 287-292 (Pubitemid 34970898)
21. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS (2004) Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10: 136-143
22. Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Brechot JM, Muley T, Grenier J (2004) CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90: 2097-2105 (Pubitemid 38869712)
23. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11: 3974-3986
24. Stieber P, Bodenmüller H, Banauch D, Hasholzner U, Dessauer A, Ofenloch-Hähnle B, Jaworek D, Fateh-Moghadam A (1993) Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem 26: 301-304 (Pubitemid 23263019)
25. Tan HT, Low J, Lim SG, Chung MCM (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276: 6880-6904
26. Tarro G, Perna A, Esposito C (2005) Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol 203: 1-5
27. Team RDC (2007) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.: Vienna, Austria
28. Vielh P, Spano JP, Grenier J, Le Chevalier T, Soria JC (2005) Molecular prognostic factors in resectable non-small cell lung cancer. Crit RevOncol Hematol 53: 193-197 (Pubitemid 40254918)
29. Wardwell NR, Massion PP (2005) Novel strategies for the early detection and prevention of lung cancer. Semin Oncol 32: 259-268
30. Xi L, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE (2006) A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res 12: 2484-2491
31. Yao H, Rahman I (2009) Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 9: 375-383
32. Yorio JT, Xie Y, Yan J, Gerber DE (2009) Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol 4: 1322-1330